Results 11 to 20 of about 21,341,502 (280)
New England Journal of Medicine, 2015 Fanciulli and Wenning's review (Jan. 15 issue) on multiple-system atrophy is comprehensive and up to date. In it, the authors state that the open-label administration of gabapentin could ameliorate cerebellar symptoms in single cases of this disease ...
Berciano, J., Gazulla, J.
core +9 more sources
FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy. [PDF]
PLoS ONE, 2013 Multiple system atrophy is a parkinsonian neurodegenerative disorder. It is cytopathologically characterized by accumulation of the protein p25α in cell bodies of oligodendrocytes followed by accumulation of aggregated α-synuclein in so-called glial ...
Christine L Kragh +12 more
doaj +3 more sources
Diagnostic challenges in multiple system atrophy
Neuropsychiatric Disease and Treatment, 2018 Diana Obelieniene,1 Sandra Bauzaite,1 Ilona Kulakiene,2 Evaldas Keleras,2 Indre Eitmonaite,3 Daiva Rastenyte1 1Department of Neurology, 2Department of Radiology, 3Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania Abstract ...
Obelieniene D +5 more
doaj +1 more source
A case of multiple system atrophy [PDF]
Journal of International Medical Research, 2019 Multiple system atrophy (MSA) is the most rapidly progressive neurodegenerative disorder among the various types of synucleinopathies. The cause of MSA remains unknown, but it can involve the extrapyramidal system, the pyramidal system, the autonomic ...
Jing Guo +4 more
doaj +3 more sources
Tremor in Multiple System Atrophy - a review
Tremor and Other Hyperkinetic Movements, 2013 Background: Multiple system atrophy (MSA) is a rare neurodegenerative movement disorder characterized by a rapidly progressive course. The clinical presentation can include autonomic failure, parkinsonism, and cerebellar signs.
Christine Kaindlstorfer +2 more
doaj +5 more sources
Medical Clinics of North America, 1999 MSA is a complex disorder, with regard to its pathology and cause as well as its clinical diagnosis and treatment. Although a number of clinical treatments may improve quality of life for these patients, given the widespread pathology present, symptomatic treatment, particularly that involving neurotransmitter replacement, is likely to remain difficult.
L, Swan, J, Dupont
+7 more sources
Seminars in Neurology, 2001 Multiple system atrophy (MSA) is an adult-onset sporadic progressive neurodegenerative disorder of unknown etiology. It is clinically characterized by the variable combination of autonomic failure, parkinsonism, cerebellar ataxia, and pyramidal signs. The present review summarizes up-to-date knowledge on the clinical diagnosis and molecular pathology ...
G K, Wenning +4 more
+7 more sources
S.S. Korsakov Journal of Neurology and Psychiatry, 2023 The article presents a progressive neurodegenerative disease — multisystem atrophy, characterized by a combination of autonomic failure and various motor disorders, including parkinsonism and/or cerebellar ataxia; etiopathogenetic factors and variants of the clinical picture are described.
M.P. Topuzova +8 more
openaire +5 more sources
Development of Therapies for Spinal Muscular Atrophy Using Gene Therapy and Nanotechnology [PDF]
, 2013 Spinal muscular atrophy (SMA) is a genetic disease which is characterized by muscle weakness and atrophy. The disease arises from mutations in the survival motor neuron 1 (SMN1) gene causing degeneration of spinal cord motor neurons.
Little, Daniel
core +6 more sources
A Case of Multiple System Atrophy (MSA) – First Presentation in a Psychiatry Service [PDF]
, 2021 A 67 years old female developed cognitive deficits, depression and anxiety as first symptoms of multiple system atrophy (MSA). In the course of an year autonomic failure, parkinsonism and cerebellar ataxia also developed.
Andra Livia BRONESCU +2 more
core +2 more sources